G Maher-Edwards

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease
    G Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Curr Alzheimer Res 7:374-85. 2010
  2. doi SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
    Gareth Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Int J Geriatr Psychiatry 26:536-44. 2011

Collaborators

Detail Information

Publications2

  1. ncbi Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease
    G Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Curr Alzheimer Res 7:374-85. 2010
    ..This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of the 5-HT6 receptor antagonist, SB-742457, in subjects with mild-to-moderate probable Alzheimer's disease (AD)...
  2. doi SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
    Gareth Maher-Edwards
    GlaxoSmithKline, Uxbridge, Middlesex, UK
    Int J Geriatr Psychiatry 26:536-44. 2011
    ..To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial...